Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Reducing Skin Cancer Risk in Redheads

By Joanne Van Zuidam | September 7, 2017

Redheads are rare. Only one to two percent of the earth’s population is gifted with the hair color. But that uniqueness comes at a price. The ginger locks are usually accompanied by freckles and fair skin, which is prone to sunburn and a higher incidence of skin cancer, including melanoma.

The strand’s red hue is due to a series of mutations in the Melanocortin 1 Receptor gene (MC1R). The mutation turns off the gene’s function and, in turn, produces red hair and fair skin. While the variants in this recessive gene has been linked to higher incidence of skin cancer, researchers have not been able to determine if the variants in MC1R, a protein crucial for pigmentation in humans, can be reversed.

Now, researchers from Boston University School of Medicine (BUSM) say that there is a way to reduce cancer risk in redheads. Their work has shown that MC1R is affected by a special modification process called palmitoylation that is critical for its function. By enhancing palmitoylation in the variant MC1R proteins of redheads cancer risk can be reduced.

Much public health work has emphasized prevention by reducing sun exposure, particularly to DNA-damaging UV rays, but redheads bear a higher burden of disease making alternative risk reductions strategies and area of active interest.

“Up until now our understanding of the molecular biology of melanomagenesis (developing melanoma cancer) lacks explanations for how MC1R is affected by UV radiation, why redheads are more prone to melanoma, and whether the activity of red hair color variants could be restored for therapeutic benefit,” explained corresponding author Rutao Cui, M.D., Ph.D., professor of pharmacology and experimental therapeutics and professor of dermatology at BUSM in a statement.

In an experimental model, the researchers used a small molecule which could increase palmitoylation of MC1R named palmostatin B, and then exposed the model to UV light. The control group, without palmostatin B treatment, was also exposed to the UV light and showed a significant higher rate of developing melanoma.

“These result suggest pharmacological activation of palmitoylation prevents melanoma skin cancer in this particular model,” said Cui.

This is the first comprehensive analysis that find stimulating palmitoylation can be used as a strategy to prevent disease, according to the researchers. “We hope our study allows for the development of a pharmacological prevention strategy for red-headed people to protect their skin and let them enjoy the sun like other people.

These findings appear in the journal Nature.


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE